Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aneta Mela

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research|August 11, 2017
Indirect costs of diabetes and its impact on the public finance: the case of PolandAndrzej Torój, Aneta Mela
Expert Review of Pharmacoeconomics & Outcomes Research|October 9, 2018
The direct and indirect costs of epilepsy in Poland estimates for 2014-2016 yearsAneta Mela, Anna Staniszewska, Witold Wrona, et al.
Frontiers in Pharmacology|October 30, 2023
Reimbursement decision-making system in Poland systematically compared to other countriesAneta Mela, Elżbieta Rdzanek, Janusz Jaroszyński, et al.
Frontiers in Pharmacology|May 31, 2021
Recommendations for the Implementation of Hospital Based HTA in Poland: Lessons Learned From International ExperienceMałgorzata Gałązka-Sobotka, Iwona Kowalska-Bobko, Krzysztof Lach, et al.
Annals of Agricultural and Environmental Medicine : AAEM|December 28, 2020
Prevalence and selected determinants of the risk of problem gambling among Polish secondary school studentsIwona Niewiadomska, Lech Panasiuk, Joanna Chwaszcz, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 23, 2024
AOTMiT reimbursement recommendations compared to other HTA agenciesAneta Mela, Dorota Lis, Elżbieta Rdzanek, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 21, 2024
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agencyAneta Mela, Andrzej Tysarowski, Elżbieta Rdzanek, et al.
Frontiers in Pharmacology|March 20, 2023
Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumabMaciej Niewada, Tomasz Macioch, Magdalena Konarska, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 28, 2022
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncologyAneta Mela, Elżbieta Rdzanek, Andrzej Tysarowski, et al.
Nutrients|January 11, 2024
Strontium Ranelate and Strontium Chloride Supplementation Influence on Bone Microarchitecture and Bone Turnover Markers-A Preliminary StudyKarolina Turżańska, Agnieszka Tomczyk-Warunek, Maciej Dobrzyński, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Expert Review of Pharmacoeconomics & Outcomes Research|August 11, 2017
Indirect costs of diabetes and its impact on the public finance: the case of PolandAndrzej Torój, Aneta Mela
Expert Review of Pharmacoeconomics & Outcomes Research|October 9, 2018
The direct and indirect costs of epilepsy in Poland estimates for 2014-2016 yearsAneta Mela, Anna Staniszewska, Witold Wrona, et al.
Frontiers in Pharmacology|October 30, 2023
Reimbursement decision-making system in Poland systematically compared to other countriesAneta Mela, Elżbieta Rdzanek, Janusz Jaroszyński, et al.
Frontiers in Pharmacology|May 31, 2021
Recommendations for the Implementation of Hospital Based HTA in Poland: Lessons Learned From International ExperienceMałgorzata Gałązka-Sobotka, Iwona Kowalska-Bobko, Krzysztof Lach, et al.
Annals of Agricultural and Environmental Medicine : AAEM|December 28, 2020
Prevalence and selected determinants of the risk of problem gambling among Polish secondary school studentsIwona Niewiadomska, Lech Panasiuk, Joanna Chwaszcz, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 23, 2024
AOTMiT reimbursement recommendations compared to other HTA agenciesAneta Mela, Dorota Lis, Elżbieta Rdzanek, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 21, 2024
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agencyAneta Mela, Andrzej Tysarowski, Elżbieta Rdzanek, et al.
Frontiers in Pharmacology|March 20, 2023
Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumabMaciej Niewada, Tomasz Macioch, Magdalena Konarska, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 28, 2022
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncologyAneta Mela, Elżbieta Rdzanek, Andrzej Tysarowski, et al.
Nutrients|January 11, 2024
Strontium Ranelate and Strontium Chloride Supplementation Influence on Bone Microarchitecture and Bone Turnover Markers-A Preliminary StudyKarolina Turżańska, Agnieszka Tomczyk-Warunek, Maciej Dobrzyński, et al.
Pageof 2